{"nctId":"NCT00384189","briefTitle":"A Comparative Study of Inhaled Ciclesonide Versus Placebo in Children (6-11 Years) With Asthma","startDateStruct":{"date":"2006-09"},"conditions":["Asthma"],"count":1080,"armGroups":[{"label":"Ciclesonide 40 µg","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Ciclesonide","Drug: Placebo","Drug: Salbutamol"]},{"label":"Ciclesonide 80 µg","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Ciclesonide","Drug: Placebo","Drug: Salbutamol"]},{"label":"Ciclesonide 160 µg","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Ciclesonide","Drug: Placebo","Drug: Salbutamol"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo","Drug: Salbutamol"]}],"interventions":[{"name":"Ciclesonide","otherNames":[]},{"name":"Placebo","otherNames":[]},{"name":"Salbutamol","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Main Inclusion Criteria:\n\n* History of asthma for at least 6 months\n* Ability to show optimal use of MDI, including inhalation technique\n* Lung function and reversibility within specified limits\n\nMain Exclusion Criteria:\n\n* Concomitant severe diseases\n* Diseases which are contraindications for the use of inhaled steroids\n* Two or more inpatient hospitalizations for asthma within the last year\n* Respiratory tract infection or asthma exacerbation within the last 30 days prior to entry into the study\n* Use of systemic steroids within the last 30 days prior to inclusion (depot steroids 6 weeks)\n* Beginning of or change in immunotherapy within the last 6 months prior to inclusion\n* Inability to follow the procedures of the study","healthyVolunteers":false,"sex":"ALL","minimumAge":"6 Years","maximumAge":"11 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Morning Peak Expiratory Flow (PEF)","description":"PEF is the maximum speed of expiration. A portable electronic PEF meter was used for the home PEF readings. The patients recorded PEF daily, in the morning immediately after getting up. Readings were done preferably at least 4 hours after use of rescue medication and before inhalation of the study medication. At each measurement, three readings were obtained in the standing position. All three values were recorded in the diary; the highest value was used for evaluation. The higher change from Baseline values are the best. Analysis of covariance (ANCOVA) model with the baseline value and age as covariates was used for analysis. Last observation carried forward.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.23","spread":"2.69"},{"groupId":"OG001","value":"14.79","spread":"2.60"},{"groupId":"OG002","value":"17.37","spread":"2.68"},{"groupId":"OG003","value":"5.40","spread":"3.71"}]}]}]},{"type":"SECONDARY","title":"Time to First Event of Lack of Efficacy (LOE) by Week 12","description":"Kaplan Meier Estimates of the probability of not experiencing LOE by Week 12 was measured. LOE was reached if any of the following criteria occurred during the treatment period: • asthma exacerbation (a worsening of asthma symptoms requiring a change in medication; • nocturnal awakenings due to asthma on any 4 or more nights during any 7-consecutive-day period; • use of more than 8 puffs/day of salbutamol on any 4 or more days during any 7-consecutive-day period; • decrease in morning PEF to \\<80% of randomization value on any 4 consecutive days during the treatment period.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"72.8","spread":null},{"groupId":"OG001","value":"74.5","spread":null},{"groupId":"OG002","value":"73.2","spread":null},{"groupId":"OG003","value":"66.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Days With Asthma Control Based on Symptoms, Use of Rescue Medication, Morning PEF and PEF Fluctuation","description":"Control of asthma was evaluated on a daily basis (24 hours) using the following variables: asthma symptoms, use of rescue medication, morning (am) PEF and PEF fluctuation. The median percentage of days with asthma control is presented.","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.14","spread":null},{"groupId":"OG001","value":"10.53","spread":null},{"groupId":"OG002","value":"6.67","spread":null},{"groupId":"OG003","value":"0.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Lung Function Variable Forced Expiratory Volume in One Second (FEV1)","description":"Spirometry was performed according to local standards. FEV1 is the maximal amount of air forcefully exhaled from the lungs in one second. Higher change numbers indicate better lung function.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.123","spread":"0.015"},{"groupId":"OG001","value":"0.122","spread":"0.015"},{"groupId":"OG002","value":"0.139","spread":"0.015"},{"groupId":"OG003","value":"0.039","spread":"0.022"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Lung Function Variable PEF by Spirometry","description":"Spirometry was performed according to local standards. PEF is the maximum speed of expiration. Analysis was ANCOVA with factors value at Baseline, treatment, age, sex, center pool, ICS pretreatment, spacer use and asthma severity. Higher change numbers indicate better lung function.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.68","spread":"2.61"},{"groupId":"OG001","value":"21.71","spread":"2.51"},{"groupId":"OG002","value":"22.25","spread":"2.61"},{"groupId":"OG003","value":"15.13","spread":"3.69"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Morning PEF From Diary","description":"PEF is the maximum speed of expiration. A portable electronic PEF meter was used for the home PEF readings. The patients recorded PEF daily, in the morning immediately after getting up. Readings were done preferably at least 4 hours after use of rescue medication and before inhalation of the study medication. At each measurement, three readings were obtained in the standing position. All three values were recorded in the diary; the highest value was used for evaluation. The higher change from Baseline values are the best. Analysis of covariance (ANCOVA) model with the Baseline value and age as covariates was used for analysis.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.61","spread":"1.55"},{"groupId":"OG001","value":"9.20","spread":"1.50"},{"groupId":"OG002","value":"11.54","spread":"1.54"},{"groupId":"OG003","value":"4.54","spread":"2.13"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.82","spread":"1.89"},{"groupId":"OG001","value":"11.95","spread":"1.83"},{"groupId":"OG002","value":"12.26","spread":"1.89"},{"groupId":"OG003","value":"4.20","spread":"2.61"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.36","spread":"2.08"},{"groupId":"OG001","value":"11.11","spread":"2.01"},{"groupId":"OG002","value":"13.15","spread":"2.07"},{"groupId":"OG003","value":"6.74","spread":"2.87"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.63","spread":"2.18"},{"groupId":"OG001","value":"13.27","spread":"2.12"},{"groupId":"OG002","value":"15.60","spread":"2.18"},{"groupId":"OG003","value":"6.31","spread":"3.02"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.86","spread":"2.23"},{"groupId":"OG001","value":"13.33","spread":"2.16"},{"groupId":"OG002","value":"15.39","spread":"2.22"},{"groupId":"OG003","value":"9.67","spread":"3.08"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.91","spread":"2.30"},{"groupId":"OG001","value":"13.26","spread":"2.23"},{"groupId":"OG002","value":"14.71","spread":"2.29"},{"groupId":"OG003","value":"7.64","spread":"3.18"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.57","spread":"2.37"},{"groupId":"OG001","value":"15.05","spread":"2.30"},{"groupId":"OG002","value":"14.14","spread":"2.36"},{"groupId":"OG003","value":"6.21","spread":"3.28"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.57","spread":"2.39"},{"groupId":"OG001","value":"15.92","spread":"2.31"},{"groupId":"OG002","value":"13.63","spread":"2.38"},{"groupId":"OG003","value":"7.05","spread":"3.30"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.26","spread":"2.44"},{"groupId":"OG001","value":"16.02","spread":"2.36"},{"groupId":"OG002","value":"13.23","spread":"2.43"},{"groupId":"OG003","value":"7.88","spread":"3.37"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.35","spread":"2.48"},{"groupId":"OG001","value":"16.79","spread":"2.40"},{"groupId":"OG002","value":"14.59","spread":"2.47"},{"groupId":"OG003","value":"7.66","spread":"3.43"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.12","spread":"2.60"},{"groupId":"OG001","value":"15.97","spread":"2.52"},{"groupId":"OG002","value":"16.24","spread":"2.59"},{"groupId":"OG003","value":"6.80","spread":"3.60"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.93","spread":"2.72"},{"groupId":"OG001","value":"15.43","spread":"2.64"},{"groupId":"OG002","value":"17.59","spread":"2.71"},{"groupId":"OG003","value":"6.41","spread":"3.76"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Evening PEF From Diary","description":"PEF is the maximum speed of expiration. A portable electronic PEF meter was used for the home PEF readings. The patients recorded PEF daily, in the morning immediately after getting up. Readings were done preferably at least 4 hours after use of rescue medication and before inhalation of the study medication. At each measurement, three readings were obtained in the standing position. All three values were recorded in the diary; the highest value was used for evaluation. The higher change from Baseline values are the best. Analysis of covariance (ANCOVA) model with the Baseline value and age as covariates was used for analysis.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.16","spread":"2.54"},{"groupId":"OG001","value":"9.37","spread":"2.46"},{"groupId":"OG002","value":"12.71","spread":"2.53"},{"groupId":"OG003","value":"4.02","spread":"3.52"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Diurnal PEF Fluctuations","description":"PEF is the maximum speed of expiration. A portable electronic PEF meter was used for the home PEF readings. The patients recorded PEF daily, in the morning immediately after getting up. Readings were done preferably at least 4 hours after use of rescue medication and before inhalation of the study medication. At each measurement, three readings were obtained in the standing position. All three values were recorded in the diary; the highest value was used for evaluation. A negative change from Baseline indicates improvement. Analysis of covariance (ANCOVA) model with the Baseline value and age as covariates was used for analysis.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.841","spread":"9.942"},{"groupId":"OG001","value":"-1.209","spread":"10.686"},{"groupId":"OG002","value":"-1.192","spread":"11.290"},{"groupId":"OG003","value":"0.214","spread":"9.453"}]}]}]},{"type":"SECONDARY","title":"Change in Asthma Symptom Total Score","description":"Measurements of both nighttime and daytime asthma symptoms were assessed on a daily basis by the patient in the electronic diary, according to the following scales: Nighttime Asthma Score using a 5 point scale: 0=no asthma symptoms, slept through the night to 4=bad night, awake most of the night because of asthma. Daytime Asthma Score using a 5 point scale: 0=very well, no asthma symptoms to 4=asthma very bad, unable to carry out daily activities as usual. Total possible overall daily score range from 0(best) to 4 (worst). A negative change from Baseline indicated improvement.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.916","spread":"1.265"},{"groupId":"OG001","value":"-0.983","spread":"1.209"},{"groupId":"OG002","value":"-0.879","spread":"1.270"},{"groupId":"OG003","value":"-0.572","spread":"1.483"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.529","spread":"0.682"},{"groupId":"OG001","value":"-0.553","spread":"0.721"},{"groupId":"OG002","value":"-0.517","spread":"0.662"},{"groupId":"OG003","value":"-0.354","spread":"0.801"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.392","spread":"0.775"},{"groupId":"OG001","value":"-0.435","spread":"0.672"},{"groupId":"OG002","value":"-0.350","spread":"0.791"},{"groupId":"OG003","value":"-0.233","spread":"0.858"}]}]}]},{"type":"SECONDARY","title":"Change in Use of Rescue Medications","description":"The daily use of rescue medication (salbutamol) was recorded in the electronic diary in the morning and the evening. A negative change from Baseline indicates improvement.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.872","spread":"1.634"},{"groupId":"OG001","value":"-0.999","spread":"1.523"},{"groupId":"OG002","value":"-0.886","spread":"1.771"},{"groupId":"OG003","value":"-0.527","spread":"1.931"}]}]}]},{"type":"SECONDARY","title":"Percentage of Days With Asthma Control Based on Symptoms, Use of Rescue Medication and Morning PEF","description":"Control of asthma was evaluated on a daily basis (24 hours) using the following variables: asthma symptoms, use of rescue medication, and morning (am) PEF. The median percentage of days with asthma control is presented.","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.33","spread":null},{"groupId":"OG001","value":"13.64","spread":null},{"groupId":"OG002","value":"13.04","spread":null},{"groupId":"OG003","value":"0.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Pediatric Asthma Quality of Life Questionnaire Standard [PAQLQ(S)] Overall Score","description":"PAQLQS is a disease specific instrument to assess the impact of asthma on the patient's quality of life. The PAQLQS consists of 23 items in 3 domains evaluating activity limitations, symptoms and emotional function. Patients answered each question using a 7-point scale from 1= maximum impairment to 7=no impairment) about their experience during the previous week. Total possible score ranging from 23 (worst) to 161(best). Higher change from Baseline scores are the best. Analysis of covariance (ANCOVA) model with the baseline value and age as covariates was used for analysis.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.78","spread":"0.07"},{"groupId":"OG001","value":"0.71","spread":"0.07"},{"groupId":"OG002","value":"0.72","spread":"0.07"},{"groupId":"OG003","value":"0.43","spread":"0.10"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Pediatric Asthma Caregiver's Quality of Life Questionnaire (PACQLQ) Overall","description":"PACQLQ assesses the impact of the child's asthma on the quality of life of the caregiver. The PACQLQ consists of 13 items in 2 domains evaluating activity limitations and emotional function. Caregivers answered each question using a 7-point scale from 1= maximum impairment to 7=no impairment about their experience during the previous week. Total possible score ranging from 13 (worst) to 91(best). Higher change from Baseline scores are the best. Analysis of covariance (ANCOVA) model with the baseline value and age as covariates was used for analysis.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.82","spread":"0.08"},{"groupId":"OG001","value":"0.88","spread":"0.08"},{"groupId":"OG002","value":"0.84","spread":"0.08"},{"groupId":"OG003","value":"0.71","spread":"0.12"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":305},"commonTop":["Upper respiratory tract infection","Pharyngitis","Nasopharyngitis"]}}}